Want to create an interactive transcript for this episode?
Podcast: PeerView Clinical Pharmacology CME/CNE/CPE Video
Episode: Dr. Toby A. Eyre, MBChB, DipMedEd, MRCP, FRCPath, MD - Fixing the Target on Aggressive Lymphoma: Guidance on the Next Phase of Integrating Targeted Agents Into MCL and DLBCL Management
Description: Go online to PeerView.com/YVY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Across B-cell non-Hodgkin lymphoma settings, the use of targeted agents has in many instances eclipsed the use of standard chemoimmunotherapy. In more aggressive B-cell lymphomas, including in mantle cell lymphoma (MCL) and diffuse large B-cell lymphoma (DLBCL), progress with targeted therapy has been slower. However, new evidence with BTK inhibitors in MCL and DLBCL indicates that they may boost efficacy when added to proven therapeutic platforms or when used in disease subtypes defined by molecular (eg, activated B-cell...